Last update 09 Jun 2026

Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang )

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms
REC617
Target-
Action-
Mechanism-
Therapeutic Areas
Infectious Diseases
Active Indication
Respiratory Syncytial Virus Infections
Inactive Indication-
Originator Organization
Yikang Biological (Suzhou Co Ltd.Yikang Biological (Suzhou Co Ltd.
Active Organization
Yikang Biological (Suzhou Co Ltd.Yikang Biological (Suzhou Co Ltd.
Inactive Organization-
License Organization-
Drug Highest PhaseIND Approval
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang )
NCT07633756
/ Not yet recruitingPhase 1
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
NCT07582796
/ RecruitingPhase 1/2
A Randomized, Blinded, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted) in Adults Aged 18 Years and Older.
ChiCTR2500113441
/ CompletedPhase 2IIT
A Phase II Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 60 Years and Above
100 Clinical Results associated with Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang )
Login to view more data
100 Translational Medicine associated with Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang )
Login to view more data
100 Patents (Medical) associated with Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang )
Login to view more data
100 Deals associated with Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) (Adjuvant)(Yikang )
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Respiratory Syncytial Virus InfectionsIND Approval
China
Yikang Biological (Suzhou Co Ltd.Yikang Biological (Suzhou Co Ltd.
01 Jun 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free